

Steffen Borrmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2007087/publications.pdf>

Version: 2024-02-01

97
papers

5,532
citations

66343

42
h-index

85541

71
g-index

99
all docs

99
docs citations

99
times ranked

5619
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug-induced hypersensitivity to artemisinin-based therapies for malaria. Trends in Parasitology, 2022, 38, 136-146.	3.3	5
2	Surveillance of Plasmodium malariae infection among inhabitants of rural areas in Ouidahâ€“Kpomasseâ€“Tori Bossito health district, Benin. Parasitology Research, 2022, 121, 275-286.	1.6	3
3	Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis. Malaria Journal, 2022, 21, 106.	2.3	1
4	P. falciparum msp1 and msp2 genetic diversity in P. falciparum single and mixed infection with P. malariae among the asymptomatic population in Southern Benin. Parasitology International, 2022, 89, 102590.	1.3	5
5	Efficacy, T cell activation and antibody responses in accelerated Plasmodium falciparum sporozoite chemoprophylaxis vaccine regimens. Npj Vaccines, 2022, 7, .	6.0	3
6	Transmission of <i>Cryptosporidium</i> Species Among Human and Animal Local Contact Networks in Sub-Saharan Africa: A Multicountry Study. Clinical Infectious Diseases, 2021, 72, 1358-1366.	5.8	26
7	Comparative genomics revealed adaptive admixture in Cryptosporidium hominis in Africa. Microbial Genomics, 2021, 7, .	2.0	13
8	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	97
9	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	51
10	High ESBL-E colonization rate among children in Gabon: a follow-up study. Journal of Medical Microbiology, 2021, 70, .	1.8	2
11	Molecular surveillance and genetic divergence of rotavirus A antigenic epitopes in Gabonese children with acute gastroenteritis. EBioMedicine, 2021, 73, 103648.	6.1	6
12	Elevated Plasmodium sporozoite infection and multiple insecticide resistance in the principal malaria vectors Anopheles funestus and Anopheles gambiae in a forested locality close to the YaoundÃ© airport, Cameroon. Wellcome Open Research, 2020, 5, 146.	1.8	10
13	Controlled Human Malaria Infection (CHMI) Studies: Over 100 Years of Experience with Parasite Injections. Methods in Molecular Biology, 2019, 2013, 91-101.	0.9	8
14	Differential activity of methylene blue against erythrocytic and hepatic stages of Plasmodium. Malaria Journal, 2018, 17, 143.	2.3	20
15	Pyronaridineâ€“artesunate or dihydroartemisininâ€“piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet, The, 2018, 391, 1378-1390.	13.7	93
16	Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLoS Medicine, 2018, 15, e1002579.	8.4	47
17	Plasmodium falciparum variant erythrocyte surface antigens: a pilot study of antibody acquisition in recurrent natural infections. Malaria Journal, 2017, 16, 450.	2.3	1
18	Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLoS Medicine, 2017, 14, e1002212.	8.4	50

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 189-198.	9.1	58
20	Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. <i>Malaria Journal</i> , 2015, 14, 359.	2.3	47
21	Novel approaches to whole sporozoite vaccination against malaria. <i>Vaccine</i> , 2015, 33, 7462-7468.	3.8	48
22	An Economic Evaluation of the Posttreatment Prophylactic Effect of Dihydroartemisinin+Piperaquine Versus Artemether+Lumefantrine for First-Line Treatment of Plasmodium falciparum Malaria Across Different Transmission Settings in Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 961-966.	1.4	8
23	Whole-Genome Scans Provide Evidence of Adaptive Evolution in Malawian Plasmodium falciparum Isolates. <i>Journal of Infectious Diseases</i> , 2014, 210, 1991-2000.	4.0	62
24	PlasmoView: A Web-based Resource to Visualise Global Plasmodium falciparum Genomic Variation. <i>Journal of Infectious Diseases</i> , 2014, 209, 1808-1815.	4.0	23
25	Protection against malaria by immunization with non-attenuated sporozoites under single-dose piperaquine-tetraphosphate chemoprophylaxis. <i>Vaccine</i> , 2014, 32, 6005-6011.	3.8	18
26	A barcode of organellar genome polymorphisms identifies the geographic origin of Plasmodium falciparum strains. <i>Nature Communications</i> , 2014, 5, 4052.	12.8	130
27	Dihydroartemisinin-Piperaquine vs. Artemether-Lumefantrine for First-Line Treatment of Uncomplicated Malaria in African Children: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2014, 9, e95681.	2.5	18
28	A micro-epidemiological analysis of febrile malaria in Coastal Kenya showing hotspots within hotspots. <i>ELife</i> , 2014, 3, e02130.	6.0	115
29	Antimalarial activity of isoquine against Kenyan Plasmodium falciparum clinical isolates and association with polymorphisms in pfcr1 and pfmdr1 genes. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 786-788.	3.0	6
30	NF135.C10: A New Plasmodium falciparum Clone for Controlled Human Malaria Infections. <i>Journal of Infectious Diseases</i> , 2013, 207, 656-660.	4.0	72
31	Genome-wide screen identifies new candidate genes associated with artemisinin susceptibility in Plasmodium falciparum in Kenya. <i>Scientific Reports</i> , 2013, 3, 3318.	3.3	75
32	Preferential Invasion by Plasmodium Merozoites and the Self-Regulation of Parasite Burden. <i>PLoS ONE</i> , 2013, 8, e57434.	2.5	40
33	Pharmacokinetic and Pharmacodynamic Characteristics of a New Pediatric Formulation of Artemether-Lumefantrine in African Children with Uncomplicated Plasmodium falciparum Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5429-5429.	3.2	1
34	Fosmidomycin as an Antimalarial Agent. , 2012, , 119-137.		0
35	Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. <i>Nature</i> , 2012, 487, 375-379.	27.8	450
36	Protective immunity against malaria by "natural immunization"™: a question of dose, parasite diversity, or both?. <i>Current Opinion in Immunology</i> , 2011, 23, 500-508.	5.5	16

#	ARTICLE	IF	CITATIONS
37	Targeting Plasmodium liver stages: better late than never. Trends in Molecular Medicine, 2011, 17, 527-536.	6.7	30
38	Declining Responsiveness of Plasmodium falciparum Infections to Artemisinin-Based Combination Treatments on the Kenyan Coast. PLoS ONE, 2011, 6, e26005.	2.5	87
39	Variable lifetimes and loss mechanisms for NO ₂ and N ₂ O during the DOMINO campaign: contrasts between marine, urban and continental air. Atmospheric Chemistry and Physics, 2011, 11, 10853-10870.	4.9	55
40	Pharmacokinetic and Pharmacodynamic Characteristics of a New Pediatric Formulation of Artemether-Lumefantrine in African Children with Uncomplicated Plasmodium falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2011, 55, 3994-3999.	3.2	24
41	Arrested Plasmodium liver stages as experimental anti-malaria vaccines. Hum Vaccin, 2011, 7, 16-21.	2.4	16
42	Induction of Antimalaria Immunity by Pyrimethamine Prophylaxis during Exposure to Sporozoites Is Curtailed by Parasite Resistance. Antimicrobial Agents and Chemotherapy, 2011, 55, 2760-2767.	3.2	31
43	Population Genetic Analysis of Plasmodium falciparum Parasites Using a Customized Illumina GoldenGate Genotyping Assay. PLoS ONE, 2011, 6, e20251.	2.5	63
44	Temporal Association of Acute Hepatitis A and Plasmodium falciparum Malaria in Children. PLoS ONE, 2011, 6, e21013.	2.5	6
45	Spatial Distribution of Bednet Coverage under Routine Distribution through the Public Health Sector in a Rural District in Kenya. PLoS ONE, 2011, 6, e25949.	2.5	24
46	Computational Prediction of Host-Parasite Protein Interactions between P. falciparum and H. sapiens. PLoS ONE, 2011, 6, e26960.	2.5	72
47	In-situ observations of young contrails – overview and selected results from the CONCERT campaign. Atmospheric Chemistry and Physics, 2010, 10, 9039-9056.	4.9	93
48	The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem [®]) for acute uncomplicated Plasmodium falciparum malaria. Tropical Medicine and International Health, 2010, 15, 434-441.	2.3	42
49	In Vitro Activities of Quinine and Other Antimalarials and Polymorphisms in Plasmodium Isolates from Kenya. Antimicrobial Agents and Chemotherapy, 2010, 54, 3302-3307.	3.2	39
50	Reply to Mikolajczak et al. Journal of Infectious Diseases, 2010, 201, 1271-1272.	4.0	0
51	Natural Immunization Against Malaria: Causal Prophylaxis with Antibiotics. Science Translational Medicine, 2010, 2, 40ra49.	12.4	118
52	Nitric oxide generation in children with malaria and the NOS2G-954C promoter polymorphism. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 299, R1248-R1253.	1.8	15
53	Aerosol layers from the 2008 eruptions of Mount Okmok and Mount Kasatochi: In situ upper troposphere and lower stratosphere measurements of sulfate and organics over Europe. Journal of Geophysical Research, 2010, 115, .	3.3	46
54	Defining Clinical Malaria: The Specificity and Incidence of Endpoints from Active and Passive Surveillance of Children in Rural Kenya. PLoS ONE, 2010, 5, e15569.	2.5	40

#	ARTICLE	IF	CITATIONS
55	Chlorproguanil~Dapsone~Artesunate versus Artemether~Lumefantrine: A Randomized, Double-Blind Phase III Trial in African Children and Adolescents with Uncomplicated Plasmodium falciparum Malaria. PLoS ONE, 2009, 4, e6682.	2.5	58
56	Dihydroartemisinin-Piperaquine and Artemether-Lumefantrine for Treating Uncomplicated Malaria in African Children: A Randomised, Non-Inferiority Trial. PLoS ONE, 2009, 4, e7871.	2.5	125
57	In Vitro Activity of Antifolate and Polymorphism in Dihydrofolate Reductase of Plasmodium falciparum Isolates from the Kenyan Coast: Emergence of Parasites with Ile-164-Leu Mutation. Antimicrobial Agents and Chemotherapy, 2009, 53, 3793-3798.	3.2	46
58	In Vitro Activities of Piperaquine, Lumefantrine, and Dihydroartemisinin in Kenyan Plasmodium falciparum Isolates and Polymorphisms in pfcrt and pfmdr1. Antimicrobial Agents and Chemotherapy, 2009, 53, 5069-5073.	3.2	140
59	In Vivo and In Vitro Efficacy of Amodiaquine against Plasmodium falciparum in an Area of Continued Use of 4-Aminoquinolines in East Africa. Journal of Infectious Diseases, 2009, 199, 1575-1582.	4.0	23
60	Vaccine-Like Immunity against Malaria by Repeated Causal Prophylactic Treatment of Liver Stage Plasmodium Parasites. Journal of Infectious Diseases, 2009, 199, 899-903.	4.0	55
61	Chloroquine resistance before and after its withdrawal in Kenya. Malaria Journal, 2009, 8, 106.	2.3	136
62	Lack of multiple copies of pfmdr1 gene in Papua New Guinea. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, 1151-1153.	1.8	4
63	Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet, The, 2008, 372, 1819-1827.	13.7	117
64	Effects of Plasmodium falciparum Parasite Population Size and Patient Age on Early and Late Parasitological Outcomes of Antimalarial Treatment in Children. Antimicrobial Agents and Chemotherapy, 2008, 52, 1799-1805.	3.2	16
65	Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria. PLoS Medicine, 2008, 5, e227.	8.4	14
66	Delayed parasite elimination in human infections treated with clindamycin parallels ~delayed death™ of Plasmodium falciparum in vitro. International Journal for Parasitology, 2007, 37, 777-785.	3.1	27
67	Lactic Acidosis in Gabonese Children with Severe Malaria Is Unrelated to Dehydration. Clinical Infectious Diseases, 2006, 42, 1719-1725.	5.8	21
68	Fosmidomycin plus Clindamycin for Treatment of Pediatric Patients Aged 1 to 14 Years with Plasmodium falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2006, 50, 2713-2718.	3.2	112
69	Clinical and Parasitological Characteristics of Puerperal Malaria. Journal of Infectious Diseases, 2005, 191, 1005-1009.	4.0	44
70	Short-Course Regimens of Artesunate-Fosmidomycin in Treatment of Uncomplicated Plasmodium falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2005, 49, 3749-3754.	3.2	74
71	Artesunate-Clindamycin versus Quinine-Clindamycin in the Treatment of Plasmodium falciparum Malaria: A Randomized Controlled Trial. Clinical Infectious Diseases, 2005, 40, 1777-1784.	5.8	64
72	SHORT REPORT: PILOTING PAPERLESS DATA ENTRY FOR CLINICAL RESEARCH IN AFRICA. American Journal of Tropical Medicine and Hygiene, 2005, 72, 301-303.	1.4	27

#	ARTICLE	IF	CITATIONS
73	Fosmidomycin+Clindamycin for the Treatment of Plasmodium falciparum Malaria. Journal of Infectious Diseases, 2004, 190, 1534-1540.	4.0	132
74	Long-Term Treatment of Intestinal Helminths Increases Mite Skin-Test Reactivity in Gabonese Schoolchildren. Journal of Infectious Diseases, 2004, 189, 892-900.	4.0	305
75	Fosmidomycin+Clindamycin for Plasmodium falciparum Infections in African Children. Journal of Infectious Diseases, 2004, 189, 901-908.	4.0	105
76	Assessment of Volume Depletion in Children with Malaria. PLoS Medicine, 2004, 1, e18.	8.4	58
77	Randomized controlled trial of a traditional preparation of Artemisia annua L. (Annual Wormwood) in the treatment of malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004, 98, 318-321.	1.8	116
78	SHORT REPORT: EVALUATION OF A SIMPLE AND INEXPENSIVE PHOTOMETRIC DEVICE FOR THE MEASUREMENT OF HEMOGLOBIN. American Journal of Tropical Medicine and Hygiene, 2004, 71, 691-692.	1.4	6
79	Short report: evaluation of a simple and inexpensive photometric device for the measurement of hemoglobin. American Journal of Tropical Medicine and Hygiene, 2004, 71, 691-2.	1.4	2
80	Severe malaria in a splenectomised Gabonese woman. Wiener Klinische Wochenschrift, 2003, 115, 63-65.	1.9	8
81	Fosmidomycin for the treatment of malaria. Parasitology Research, 2003, 90, S71-S76.	1.6	131
82	Atovaquone/Proguanil. Drugs, 2003, 63, 597-623.	10.9	71
83	Short-Course Artesunate Treatment of Uncomplicated Plasmodium falciparum Malaria in Gabon. Antimicrobial Agents and Chemotherapy, 2003, 47, 901-904.	3.2	35
84	Atovaquone and Proguanil versus Amodiaquine for the Treatment of Plasmodium falciparum Malaria in African Infants and Young Children. Clinical Infectious Diseases, 2003, 37, 1441-1447.	5.8	29
85	Antibody Responses to Plasmodium falciparum Merozoite Surface Protein-1 and Efficacy of Amodiaquine in Gabonese Children with P. falciparum Malaria. Journal of Infectious Diseases, 2003, 187, 1137-1141.	4.0	27
86	Evidence for the efficacy of artesunate in asymptomatic Plasmodium malariae infections. Journal of Antimicrobial Chemotherapy, 2002, 50, 751-754.	3.0	14
87	Immune Responses Induced by Repeated Treatment Do Not Result in Protective Immunity to Schistosoma haematobium: Interleukin (IL)-5 and IL-10 Responses. Journal of Infectious Diseases, 2002, 186, 1474-1482.	4.0	45
88	Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet, The, 2002, 359, 1365-1372.	13.7	259
89	Fosmidomycin for malaria. Lancet, The, 2002, 360, 1941-1942.	13.7	219
90	Polymorphisms in the parasite genes for pfcrt and pfmdr-1 as molecular markers for chloroquine resistance in Plasmodium falciparum in Lambaré, Gabon. Parasitology Research, 2002, 88, 475-476.	1.6	19

#	ARTICLE	IF	CITATIONS
91	Age-dependent enhancement of IFN- γ responses to Plasmodium falciparum liver stage antigen-1 T cell epitopes. Parasitology Research, 2002, 88, 1083-1089.	1.6	8
92	Reassessment of the resistance of Plasmodium falciparum to chloroquine in Gabon: implications for the validity of tests in vitro vs. in vivo. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2002, 96, 660-663.	1.8	45
93	JMM - Past and Present. Journal of Molecular Medicine, 2002, 80, 327-328.	3.9	0
94	The Prevalence of Parasite Infestation and House Dust Mite Sensitization in Gabonese Schoolchildren. International Archives of Allergy and Immunology, 2001, 126, 231-238.	2.1	111
95	Artesunate and Praziquantel for the Treatment of Schistosoma haematobium Infections: A Double-blind, Randomized, Placebo-controlled Study. Journal of Infectious Diseases, 2001, 184, 1363-1366.	4.0	91
96	High Prevalence of Human Antibodies to Recombinant Duffy Binding-Like \pm Domains of the Plasmodium falciparum -Infected Erythrocyte Membrane Protein 1 in Semi-Immune Adults Compared to That in Nonimmune Children. Infection and Immunity, 2001, 69, 7603-7609.	2.2	32
97	Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet, The, 2000, 355, 2041-2045.	13.7	126